Evidence map›Paper›PMID 36247304›Full record

ArticleAmerican journal of translational research2022

Changes of serum P62 and Beclin 1 in patients with pulmonary embolism during treatment and their predictive value for efficacy.

Xuehui Zhang, Liu Huang, Lijiang Shao, Xuxia Chen, Jinguo Chu, Xueqin Chen

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xuehui ZhangDepartment of General Practice, Ningbo First Hospital No. 59 Liuting Street, Haishu District, Ningbo, Zhejiang Province, P. R. China.
Liu HuangDepartment of General Practice, Ningbo First Hospital No. 59 Liuting Street, Haishu District, Ningbo, Zhejiang Province, P. R. China.
Lijiang ShaoDepartment of Emergency, Ningbo First Hospital No. 59 Liuting Street, Haishu District, Ningbo, Zhejiang Province, P. R. China.
Xuxia ChenDepartment of Emergency, Ningbo First Hospital No. 59 Liuting Street, Haishu District, Ningbo, Zhejiang Province, P. R. China.
Jinguo ChuDepartment of General Practice, Ningbo First Hospital No. 59 Liuting Street, Haishu District, Ningbo, Zhejiang Province, P. R. China.
Xueqin ChenHospital Quality Management Office, Ningbo First Hospital No. 59 Liuting Street, Haishu District, Ningbo, Zhejiang Province, P. R. China.
Ningbo First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study was designed to analyze the changes of serum P62 and Beclin 1 in patients with acute pulmonary embolism (APE) during treatment and their predictive value for efficacy.

methodsIn this retrospective study, 84 patients diagnosed as APE in Ningbo First Hospital from January 2020 to January 2022 were enrolled and assigned to a patient group, and 40 healthy individuals who underwent physical examination in Ningbo First Hospital during the same time period were assigned to a control group. Serum P62 and Beclin 1 expressions were compared between the two groups, and receiver operating characteristic (ROC) curves were drawn to analyze the diagnostic value of serum P62 and Beclin 1. The changes of serum P62 and Beclin 1 before and after treatment were evaluated. The correlations of P62 and Beclin 1 levels with the efficacy in patients were analyzed, and corresponding ROC curves were drawn. Additionally, the expressions of serum P62 and Beclin 1 in patients with different disease degrees were determined, and their expressions in relapsed patients were compared before treatment.

resultsThe patient group showed significantly lower level of serum P62 but higher level of Beclin 1 than the control group (P<0.05). The areas of under the curves (AUCs) of P62 and Beclin 1 in diagnosing APE were 0.888 and 0.795 respectively. After treatment, patients showed significantly increased P62 expression (P<0.05) and significantly decreased Beclin 1 expression (P<0.01). The P62 expression increased with the relief of patient's disease, with a positive correlation with the patient's disease condition, while the Beclin 1 expression decreased with the relief of patient's disease, with a negative correlation with the patient's disease condition (P<0.05). In addition, the improved group showed significantly higher serum P62 expression (P<0.05) and significantly lower serum Beclin 1 expression than the non-improved group (P<0.05), and the AUCs of P62 and Beclin 1 in predicting the efficacy in patients with APE were 0.801 and 0.675, respectively. The relapsed group showed significantly lower serum P62 expression (P<0.05) and significantly higher Beclin 1 expression than the non-relapsed group (P<0.05), and the AUCs of P62 and Beclin 1 in predicting the recurrence of APE were 0.815 and 0.769, respectively.

conclusionIn patients with APE, serum P62 decreased, but serum Beclin 1 increased. So, both indictors can be applied for diagnosis, efficacy prediction and recurrence prediction of APE.

Indexed as

Acute pulmonary embolismautophagyBeclin 1diagnosisefficacy predictionP62recurrence prediction

Identifiers

PMID36247304
PMCPMC9556509
OpenAlexW4306669195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.